Carbocisteine Biogaran 2% coux grasse enfants Sans Sucre 125 ml is indicated for the treatment of bronchial secretion disorders, particularly during acute bronchial conditions: acute bronchitis and acute episodes of chronic bronchopneumopathy.
Directions for use Carbocistéine Biogaran 2% coux grasse enfants Sans Sucre 125 ml
Dosage
This speciality is suitable for patients on a hypoglucidic or hypocaloric diet.
One 5 ml measuring spoon contains 100 mg carbocisteine.
Pediatric population
Children aged 2 to 5
200 mg daily, divided into 2 doses, i.e. 1 measuring spoon of 5 ml twice a day.
Children over 5 years of age
300 mg daily, divided into 3 doses, i.e. 1 measuring spoon of 5 ml 3 times a day.
Duration of treatment
8 to 10 days.
Method of administration: Oral.
Composition Carbocistéine Biogaran 2% coux grasse enfants Sans Sucre 125 ml
oral solution: Carbocisteine 2 g/100 ml.
Excipients : Hydroxyethylcellulose, Sodium saccharin, Sodium methyl parahydroxybenzoate (E 219), Caramel flavoring (1), Vanilla flavoring (2), (Cocoa alcohol, Cocoa spirit, Grape alcohol, Grape spirit, Caramel sugar, (Saccharose, Fructose, Galactose), Vanilla extract, Vanillin, Coffee extract, Anisic aldehyde, Propylene glycol, Ethyl alcohol), Sodium hydroxide, Purified water.
1 measuring spoon of 5 ml contains 100 mg carbocisteine.
1 measuring spoon of 5 ml = 0.24 Kcal.
Notable excipients: glucose, fructose, sucrose, sodium methyl parahydroxybenzoate (E219) and ethanol.
Contraindications:
- Hypersensitivity to carbocistein, methyl parahydroxybenzoate, other parahydroxybenzoate salts or any of the excipients listed under Excipients.
- In case of active peptic ulcer.
- Infants (under 2 years of age) (see Warnings and precautions for use).
Warnings and other special precautions for use:
In the event of oily, purulent sputum, fever or chronic bronchial or lung disease, re-examine the clinical situation.
Productive coughs, which represent a fundamental element of bronchopulmonary defense, should be respected.
The combination of bronchial mucomodifiers with cough suppressants and/or secretion-drying substances (atropinics) is irrational.
Mucolytics can induce bronchial overcrowding in infants. Their capacity to drain bronchial mucus is limited by the physiological characteristics of the respiratory tree. They should therefore not be used in infants (see Contraindications and Adverse reactions).
Treatment should be reassessed in the event of persistent or worsening symptoms or pathology.
Caution is advised in elderly patients, in patients with a history of peptic ulcers, or in patients taking drugs that may cause gastrointestinal bleeding.
If such bleeding occurs, patients should discontinue treatment.
This medicine contains sucrose. Patients with fructose intolerance, glucose-galactose malabsorption syndrome or sucrase/isomaltase deficiency (rare hereditary diseases) should not take this medicine.
This medicine contains glucose. Patients with glucose-galactose malabsorption syndrome (a rare hereditary disease) should not take this medicine.
This medicine contains fructose. This medicine contains less than 20 mg fructose per 5 ml measuring spoon. The additive effect of concomitantly administered products containing fructose (or sorbitol) and dietary intake of fructose (or sorbitol) must be taken into account.
This medicine contains "parahydroxybenzoate" (E219) and may cause allergic reactions (possibly delayed).
This medicine contains less than 1 mmol (23 mg) per 5 ml measuring spoon, i.e. it is essentially "sodium-free".
This medicine contains 30 mg alcohol (ethanol) per 5 ml measuring spoon. The amount per measuring spoon is equivalent to less than 1 ml beer or 1 ml wine. The small amount of alcohol contained in this medicine is unlikely to have any noticeable effect.
Pregnancy and breast-feeding :
Pregnancy
Animal studies have shown no evidence of teratogenic effects.
No data are available on the use of carbocisteine in pregnant women.
Consequently, the use of carbocisteine in pregnant women is not recommended.
Breast-feeding
No data are available on the passage of carbocisteine into breast milk.
Consequently, the use of carbocisteine in breast-feeding women is not recommended.
Effects on ability to drive and use machines :
Not applicable.
Français
English
